Navigating IgA Nephropathy: Insights From a Patient With Lived Experience

07/11/24 • 21 min

In this CCO Nephrology podcast episode, hear from Kelly Chen, a nephrology nurse practitioner and patient living with IgA nephropathy, as she discusses her experiences with Dr Pietro Canetta, Associate Professor of Medicine at Columbia University and expert in glomerular diseases.

Episode outline:

Seeking and obtaining an IgAN diagnosis
Patient self-advocacy
Individualizing IgAN treatment plans
Clinical trial involvement
Burdens of IgAN: physical, emotional, social, and beyond

To learn more about IgA nephropathy, find more educational activities and resources with the links below:

Episode outline:

Seeking and obtaining an IgAN diagnosis
Patient self-advocacy
Individualizing IgAN treatment plans
Clinical trial involvement
Burdens of IgAN: physical, emotional, social, and beyond

To learn more about IgA nephropathy, find more educational activities and resources with the links below:

Previous Episode

How to Implement Earlier Hepatitis B Treatment

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:

Patient subgroups to consider for treatment outside guideline criteria
Adverse event and cost-effectiveness considerations
Integration of patient perspectives in wider treatment

Presenters:

Mark S. Sulkowski, MD, FIDSA, FAASLD
Professor of Medicine
Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York

Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Jacki Chen, PhD
Patient Advocate

Link to full program:
https://bit.ly/3TuqFHI

Link to the slides:
https://bit.ly/4a60GM4

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Next Episode

Expert Discussions: Moving Beyond Lipid Lowering to Lower Risk in ASCVD and CKD

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore the pathophysiology and novel therapeutic strategies to target residual inflammatory risk associated with ASCVD and CKD.

Episode outline:

Moving beyond lipid lowering to address residual inflammatory risk
Novel anti-inflammatory targets for ASCVD

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below: